Antibiotice Ia (ATB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Antibiotice Ia (ATB) has a cash flow conversion efficiency ratio of 0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON37.61 Million ≈ $8.64 Million USD) by net assets (RON932.07 Million ≈ $214.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Antibiotice Ia - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Antibiotice Ia's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ATB total debt and obligations for a breakdown of total debt and financial obligations.
Antibiotice Ia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Antibiotice Ia ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sanghvi Movers Limited
NSE:SANGHVIMOV
|
0.097x |
|
Esso (Thailand) Public Company Limited
BK:BSRC
|
0.222x |
|
Maui Land & Pineapple Company Inc
NYSE:MLP
|
-0.028x |
|
Sun Tekstil Sanayi ve Ticaret A.S.
IS:SUNTK
|
0.066x |
|
Lowland Investment Co
LSE:LWI
|
0.011x |
|
CARYSIL LIMITED
NSE:CARYSIL
|
0.125x |
|
Baader Bank Aktiengesellschaft
F:BWB
|
N/A |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
-0.129x |
Annual Cash Flow Conversion Efficiency for Antibiotice Ia (2022–2025)
The table below shows the annual cash flow conversion efficiency of Antibiotice Ia from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see ATB market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | RON932.07 Million ≈ $214.02 Million |
RON72.44 Million ≈ $16.63 Million |
0.078x | -26.95% |
| 2024-09-30 | RON894.31 Million ≈ $205.35 Million |
RON95.15 Million ≈ $21.85 Million |
0.106x | -26.42% |
| 2023-09-30 | RON846.96 Million ≈ $194.48 Million |
RON122.46 Million ≈ $28.12 Million |
0.145x | -19.82% |
| 2022-09-30 | RON641.43 Million ≈ $147.28 Million |
RON115.66 Million ≈ $26.56 Million |
0.180x | -- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more